Last reviewed · How we verify
NCT06891469
Effects of an Acute Dose of Caffeine on the Performance of CrossFit Athletes
NA trial testing Caffeine administration according to body mass (moderate intake- 7 mg/kg) in Healthy, Young Adults in 12 participants. Completed in 29 May 2022.
29 May 2022
Quick facts
| Lead sponsor | Democritus University of Thrace |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | triple |
| Primary purpose | other |
| Enrollment | 12 |
| Start date | 22 January 2022 |
| Primary completion | 29 May 2022 |
| Estimated completion | 29 May 2022 |
| Sites | 1 location across Greece |
Drugs / interventions tested
- Caffeine administration according to body mass (moderate intake- 7 mg/kg)
- Placebo (Biotin Capsules)
Conditions studied
- Healthy, Young Adults — all drugs for Healthy, Young Adults →
- Athletic Performance — all drugs for Athletic Performance →
Sponsor
Democritus University of Thrace
Who can join
Adults 18 to 40, male only, with Healthy, Young Adults or Athletic Performance. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial was to investigate the effect of an acute dose of caffeine on CrossFit performance in young, healthy male CrossFit athletes. The main questions it aimed to answer were whether an acute dose of caffeine, compared to placebo: * Can improve performance in a specific CrossFit workout * Leads to a reduction in the Rating of Perceived Exertion * Leads to an increase in blood lactate concentration at the end of the workout Participants had to: * Complete two sessions of a specific CrossFit training program (four rounds of five exercises, 50 seconds of exercise/10 seconds of rest), 60 minutes after consuming either anhydrous caffeine (7.1 ± 0.7 mg/kg of body mass) or an equivalent amount of placebo, aiming to perform as many repetitions as possible. * Report subjective perception of fatigue using the Borg scale at the end of each round.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06891469
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Democritus University of Thrace trials
Trials by the same sponsor.
- NCT07077967 — Luminous Efficiency Function V(λ)' of Patients That Underwent Pseudophakic Presbyopic Corrections With EDOF IOLs · recruiting
- NCT07060196 — The Impact of Artificial Lighting on the Visual Capacity of Patients With Age-Related Macular Degeneration · not yet recruiting
- NCT07061431 — In Vitro and in Vivo Evaluation of the Anti-Inflammatory and Antithrombotic Synergy of Vitamin C and Bioflavonoids in He · NA · completed
- NCT07439835 — Evaluation of the Visual Acuity Curves of an Enhanced Monofocal Intraocular Lens · completed
- NCT06460389 — Visual Outcomes After Extended Depth of Focus Intraocular Lens Implantation With and Without Digital Assistance · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06891469 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Democritus University of Thrace
- Last refreshed: 26 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06891469.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing